A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes (J2A-MC-GZP2)

Not yet recruiting

• Conditions: Obesity Overweight Type 2 Diabetes

• Registration Number: jRCT2051250035
• Lead Sponsor: Eli Lilly Japan K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-05-30
• Last Update Posted: 2025-05-30

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Have body mass index (BMI) >=25 kilograms per square meter (kg/m2) at screening
• Have type 2 diabetes
• Have hemoglobin A1c (HbA1c) >=7% and <=10% at screening
• Have a history of at least one unsuccessful dietary effort to lose body weight

Exclusion Criteria

• Have type 1 diabetes
• Have an unstable body weight within 90 days prior to screening
• Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
• Have acute or chronic hepatitis or pancreatitis
• Are taking other medications or alternative remedies to manage weight loss

Study & Design

• Study Type: Interventional
• Study Design: parallel assignment

Primary Outcome Measures

Name	Time	Method
-		Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40